Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 5 février 2020
Doi : 10.1016/j.jaad.2019.08.039
accepted : 14 August 2019
Atopic dermatitis and risk of atrial fibrillation or flutter: A 35-year follow-up study
 

Sigrun A.J. Schmidt, PhD a, b, , Morten Olsen, PhD a, c, Morten Schmidt, PhD a, d, Christian Vestergaard, DMSc b, Sinéad M. Langan, PhD e, f, Mette S. Deleuran, DMSc b, Jette L. Riis, PhD b
a Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark 
b Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark 
c Department of Radiology, Aarhus University Hospital, Aarhus, Denmark 
d Department of Cardiology, Regional Hospital West Jutland, Herning, Denmark 
e Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom 
f Health Data Research UK, London, United Kingdom 

Correspondence to: Sigrun A.J. Schmidt, PhD, Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, DK-8200, Aarhus N.Department of Clinical EpidemiologyAarhus University HospitalOlof Palmes Allé 43-45Aarhus NDK-8200
Abstract
Background

Atopic dermatitis is characterized by chronic inflammation, which is a risk factor for atrial fibrillation.

Objective

To examine the association between hospital-diagnosed atopic dermatitis and atrial fibrillation.

Methods

Using linked population-based Danish registries, we identified persons with an inpatient or outpatient hospital diagnosis of atopic dermatitis during 1977-2013 and a comparison cohort individually matched to the atopic dermatitis cohort. We followed cohorts until death, emigration, atrial fibrillation diagnosis, or end of study (January 1, 2013). We compared 35-year risk of atrial fibrillation and estimated hazard ratios with 95% confidence intervals using Cox regression, adjusting for birth year and sex. We validated 100 atopic dermatitis diagnoses from a dermatologic department through medical record review.

Results

We included 13,126 persons with atopic dermatitis and 124,211 comparators and followed them for a median of 19.3 years. The 35-year risk of atrial fibrillation was 0.81% and 0.67%, respectively. The positive predictive value of atopic dermatitis diagnoses was 99%. The hazard ratio was 1.2 (95% confidence interval 1.0-1.6) and remained increased after adjusting for various atrial fibrillation risk factors.

Limitations

Analyses were limited to persons with moderate-to-severe atopic dermatitis, and we had no lifestyle data.

Conclusion

Patients with hospital-diagnosed atopic dermatitis have a 20% increased long-term risk of atrial fibrillation, but the absolute risk remains low.

The full text of this article is available in PDF format.

Key words : atopic dermatitis, atrial fibrillation, atrial flutter, cohort study, risk factors, validation

Abbreviations used : CI, DNPR, HR



 Funding sources: Supported by a Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z to Dr Langan) and the Health Data Research UK (grant no. LOND1 to Dr Langan), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), and British Heart Foundation and Wellcome Trust.
 Conflicts of interest: None disclosed.
 IRB Approval: The study was approved by the Danish Data Protection Agency (record no. 2013-41-2237; 2016-051-000001). Danish legislation does not require approval by an ethical review board or informed consent from patients for registry-based studies. The Danish Patient Safety Authority approved access to medical records for the validation of diagnoses (record no. 3-3013-1526/1/). The study protocol is available from the corresponding author upon request.
 Reprints not available from the authors.



© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline